Login to Your Account

In The Clinic NEWS

Celgene Corp. reported success in the phase III SUNBEAM trial evaluating the efficacy and safety of ozanimod – the oral selective S1PR1 and 5 S1PR5 receptor modulator that was the crown jewel in its 2015 pick-up of Receptos Inc. – but offered few details.

The oral c-Met inhibitor tivantinib missed its primary endpoint of improving overall survival vs. placebo in a phase III hepatocellular carcinoma (HCC) study.

Gilead Sciences Inc., pressured by declining sales in its hepatitis C franchise and slower than anticipated growth in its HIV line-up, is putting its best foot forward at the Conference on Retroviruses and Opportunistic Infections in Seattle this week.

More In The Clinic Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: